Which of the following structures is spared in a modified radical mastectomy?
Ixabepilone is used in the treatment of which of the following conditions?
What is true about leiomyosarcoma of the breast?
A 43-year-old man presents with signs and symptoms of peritonitis in the right lower quadrant. The clinical impression and supportive data suggest acute appendicitis. At exploration, however, a tumor is found; frozen section suggests carcinoid features. A 2.5-cm tumor is located at the base of the appendix. What is the most appropriate surgical procedure for this tumor?
What is true about leiomyosarcoma of the breast?
Most common type of breast carcinoma is:
Which of the following statements about breast cancer is incorrect?
A 40-year-old female presents with a 4 cm breast lump involving the skin and a mobile, palpable axillary lymph node. FNAC of the lesion shows intraductal carcinoma. What is the initial management for this patient?
Prognostic stage groups in carcinoma breast include all except?
A 50-year-old lady presented with a lump in the left breast that developed suddenly over weeks. Perimenopausal symptoms are present. There is no associated family history. On examination, the lump is well-circumscribed, fluctuant, and measures 1.5 cm with an oval shape. What is the most likely diagnosis?
Explanation: ### Explanation The **Modified Radical Mastectomy (MRM)** is currently the standard surgical procedure for operable breast cancer. The defining feature of an MRM, which distinguishes it from the Halsted Radical Mastectomy, is the **preservation of the Pectoralis major muscle**. #### Why Pectoralis Major is Spared: In an MRM, the entire breast tissue (including the nipple-areola complex and fascia) is removed along with the Level I and II axillary lymph nodes. The **Pectoralis major** is left intact to provide better cosmetic results, maintain upper limb strength, and facilitate future reconstructive surgery. #### Analysis of Incorrect Options: * **B. Pectoralis minor:** In the **Patey’s modification** of MRM, the pectoralis minor is **removed** to facilitate access to Level III axillary nodes. In the **Auchincloss modification**, it is retracted or divided but usually preserved. However, since the question asks for the structure characteristically spared in MRM (as a general class), the Pectoralis major is the definitive answer. * **C. Axillary lymph nodes:** Removal of Level I and II axillary lymph nodes is a mandatory component of an MRM for staging and regional control. * **D. Nipple:** In a standard MRM, the **nipple-areola complex (NAC)** is always removed as part of the elliptical incision to ensure oncological safety. (Note: Sparing the nipple occurs only in "Nipple-Sparing Mastectomies," which is a different procedure). #### High-Yield Clinical Pearls for NEET-PG: * **Auchincloss Modification:** Spares both Pectoralis major and minor. * **Patey’s Modification:** Spares Pectoralis major but **removes** Pectoralis minor. * **Nerves at risk during MRM:** 1. **Long thoracic nerve (Nerve to Serratus Anterior):** Injury causes "Winging of Scapula." 2. **Thoracodorsal nerve (Nerve to Latissimus Dorsi):** Injury causes weakness in internal rotation and adduction. 3. **Intercostobrachial nerve:** Most commonly injured nerve; causes numbness of the inner aspect of the upper arm.
Explanation: **Explanation:** **Ixabepilone** is a semi-synthetic analog of epothilone B, a novel class of cytotoxic agents. Its primary mechanism of action involves binding directly to **β-tubulin subunits**, which stabilizes microtubules and induces cell cycle arrest at the G2-M phase, leading to apoptosis. Unlike taxanes, ixabepilone retains activity in cells that overexpress multidrug resistance (P-glycoprotein) or have specific tubulin mutations. **Why Breast Carcinoma is Correct:** Ixabepilone is FDA-approved specifically for the treatment of **metastatic or locally advanced breast cancer**. It is particularly indicated for patients who have developed resistance to anthracyclines and taxanes. It can be used as monotherapy or in combination with Capecitabine. **Why Other Options are Incorrect:** * **Melanoma:** While various microtubule inhibitors have been studied, the mainstay of systemic therapy for melanoma involves immunotherapy (Checkpoint inhibitors) and targeted therapy (BRAF/MEK inhibitors). * **Oat cell/Small cell carcinoma lung:** These are typically treated with platinum-based regimens (e.g., Cisplatin + Etoposide). While taxanes are used in non-small cell lung cancer (NSCLC), Ixabepilone is not a standard treatment for small cell variants. **High-Yield Clinical Pearls for NEET-PG:** * **Class:** Epothilone (Microtubule stabilizer). * **Indication:** Triple-negative breast cancer (TNBC) and taxane-resistant metastatic breast cancer. * **Side Effects:** Peripheral neuropathy (most common dose-limiting toxicity) and myelosuppression (neutropenia). * **Advantage:** It has a lower affinity for the P-glycoprotein efflux pump compared to Paclitaxel, making it effective in drug-resistant tumors.
Explanation: **Leiomyosarcoma of the breast** is an extremely rare primary stromal malignancy, accounting for less than 0.1% of all breast cancers. Unlike common epithelial breast cancers, it originates from the smooth muscle cells of the nipple-areolar complex or blood vessel walls. ### **Explanation of Options** * **Why B is Correct:** Leiomyosarcoma typically presents as a slow-growing, firm, and **well-encapsulated** mass. On gross examination, it often appears circumscribed, which can sometimes lead to it being misdiagnosed clinically or radiologically as a benign fibroadenoma. * **Why A is Incorrect:** Like most sarcomas, leiomyosarcoma spreads primarily via the **hematogenous route** (bloodstream) rather than the lymphatic system. Axillary lymph node involvement is exceptionally rare; therefore, routine axillary lymph node dissection (ALND) is not indicated. * **Why C is Incorrect:** Despite being slow-growing, these tumors have a high risk of **local recurrence** and potential distant metastasis (most commonly to the lungs). Long-term follow-up is essential to monitor for recurrence. * **Why D is Incorrect:** The mainstay of treatment is **Wide Local Excision (WLE)** with negative margins (at least 1 cm). Mastectomy is reserved only for very large tumors where clear margins cannot be achieved with breast-conserving surgery. ### **NEET-PG High-Yield Pearls** * **Origin:** Most commonly arises from the **subareolar region** (smooth muscle of the nipple/areola). * **Diagnosis:** Requires IHC (Immunohistochemistry). It is typically **SMA (Smooth Muscle Actin) positive** and Vimentin positive, but negative for cytokeratins and S-100. * **Prognosis:** Generally better than other breast sarcomas (like angiosarcoma) if diagnosed early and excised with clear margins. * **Key Distinction:** Unlike Phyllodes tumor, it does not have an epithelial component.
Explanation: **Explanation:** The management of appendiceal carcinoid tumors (neuroendocrine tumors) is primarily determined by the **size** and **location** of the tumor. **Why Right Hemicolectomy is correct:** While most appendiceal carcinoids are small and managed by simple appendectomy, a **Right Hemicolectomy** is indicated in the following high-risk scenarios: 1. **Size >2 cm:** Tumors larger than 2 cm have a significantly higher risk of nodal metastasis (up to 30%). 2. **Location at the Base:** Tumors at the base of the appendix can involve the cecum or compromise the surgical margin during a simple appendectomy. 3. **Invasion:** Involvement of the mesoappendix (especially >3mm), lymphovascular invasion, or high-grade histology. In this case, the tumor is **2.5 cm** and located at the **base**, making a right hemicolectomy the standard of care to ensure oncological clearance and lymph node dissection. **Why incorrect options are wrong:** * **Appendectomy:** Only sufficient for tumors **<1 cm** or tumors **1–2 cm** located at the tip/body without high-risk features. * **Segmental ileal resection:** This is not a standard oncological procedure for appendiceal tumors; it fails to address the lymphatic drainage of the appendix. * **Cecectomy:** While it removes the base, it does not provide the necessary lymphadenectomy required for a tumor >2 cm. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site** of carcinoid tumor in the GI tract: **Appendix** (overall), but **Small Intestine** (specifically ileum) is often cited as the most common site for *symptomatic* or larger carcinoids. * **Most common location** within the appendix: **Tip** (70%). * **Carcinoid Syndrome:** Rarely occurs with appendiceal carcinoids unless there are extensive liver metastases. * **Rule of Thumb:** <1 cm = Appendectomy; >2 cm = Right Hemicolectomy; 1–2 cm = Appendectomy (unless high-risk features are present).
Explanation: **Leiomyosarcoma of the breast** is an extremely rare primary stromal malignancy, accounting for less than 0.1% of all breast cancers. Unlike common breast carcinomas, it originates from the smooth muscle cells of the nipple-areolar complex or blood vessel walls. ### **Explanation of Options** * **Why B is Correct:** Leiomyosarcoma typically presents as a slow-growing, firm, and **well-encapsulated** or well-circumscribed mass. On imaging and gross pathology, it often mimics benign lesions like fibroadenomas because of this distinct encapsulation, which can lead to a delay in diagnosis. * **Why A is Incorrect:** Like most sarcomas, leiomyosarcoma spreads primarily via the **hematogenous route** (bloodstream) rather than the lymphatic system. Axillary lymph node involvement is exceedingly rare; therefore, routine axillary dissection is not indicated. * **Why C is Incorrect:** These tumors have a high risk of **local recurrence** and potential distant metastasis (commonly to the lungs). Long-term follow-up is essential to monitor for recurrence. * **Why D is Incorrect:** The mainstay of treatment is **Wide Local Excision (WLE)** with negative margins (at least 1 cm). Mastectomy is reserved only for very large tumors or cases where clear margins cannot be achieved with breast-conserving surgery. ### **NEET-PG High-Yield Pearls** * **Origin:** Most commonly arises from the subareolar region (smooth muscle of the nipple). * **Diagnosis:** Requires IHC (Immunohistochemistry). They are typically **SMA (Smooth Muscle Actin) positive** and Desmin positive, but negative for cytokeratins and S-100. * **Treatment Rule:** Sarcomas of the breast = Wide Local Excision + No Axillary Dissection (unless nodes are clinically palpable). * **Prognosis:** Generally better than other breast sarcomas if the tumor is small and completely excised.
Explanation: **Explanation:** **Invasive Ductal Carcinoma (IDC)**, now often referred to as **Invasive Carcinoma of No Special Type (NST)**, is the most common histological type of breast cancer, accounting for approximately **75–80%** of all cases. It originates in the milk ducts but breaks through the basement membrane to invade the surrounding stroma. On clinical examination, it typically presents as a hard, painless, fixed mass due to significant desmoplastic reaction (fibrosis). **Analysis of Incorrect Options:** * **A. Lobular:** Invasive Lobular Carcinoma (ILC) is the second most common type (approx. 10–15%). It is characterized by the loss of E-cadherin and a high propensity for being bilateral and multicentric. * **B. Sarcoma:** Primary breast sarcomas (e.g., angiosarcoma) are extremely rare, accounting for less than 1% of all breast malignancies. * **D. Granuloma:** This is not a carcinoma; it refers to a chronic inflammatory condition (e.g., Idiopathic Granulomatous Mastitis or Tuberculosis of the breast), not a malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Upper Outer Quadrant (due to maximum glandular tissue). * **Most common benign tumor:** Fibroadenoma (Breast Mouse). * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Staging:** The TNM system is used, but the **Nottingham Modification of the Scarff-Bloom-Richardson scoring system** is the gold standard for histological grading (based on tubule formation, nuclear pleomorphism, and mitotic count). * **Molecular Subtype:** Luminal A (ER/PR positive, HER2 negative) is the most common molecular subtype and carries the best prognosis.
Explanation: **Explanation:** The correct answer is **D** because it is a false statement. In reality, **prolonged breastfeeding is a protective factor** against breast cancer. The underlying medical concept is the reduction of "ovulatory cycles." Breastfeeding delays the return of ovulation (lactational amenorrhea), thereby reducing the lifetime exposure of breast tissue to endogenous estrogen and progesterone, which are known promoters of mammary cell proliferation. **Analysis of other options:** * **Option A:** Family history is a significant risk factor. Having a first-degree relative (mother, sister, or daughter) with breast cancer approximately doubles a woman's risk. * **Option B:** Paget’s disease of the nipple is characterized by malignant cells (Paget cells) in the epidermis. It is almost always associated with an underlying **Ductal Carcinoma in Situ (DCIS)** or invasive ductal carcinoma. * **Option C:** Nulliparity (never giving birth) and late age at first pregnancy are well-established risk factors. Early pregnancy and parity lead to terminal differentiation of breast epithelium, making it less susceptible to carcinogenic changes. **High-Yield NEET-PG Pearls:** * **Protective Factors:** Early pregnancy (<20 years), multiparity, prolonged breastfeeding, and early menopause. * **Risk Factors:** Early menarche (<12 years), late menopause (>55 years), HRT, obesity (post-menopausal), and BRCA1/BRCA2 mutations. * **Most Common Site:** Upper Outer Quadrant (60%). * **Paget’s Disease:** Pathognomonic finding is the presence of large, pale **Paget cells** with prominent nucleoli; it clinically mimics eczema but does not respond to topical steroids.
Explanation: ### Explanation **Correct Answer: B. Neoadjuvant Chemotherapy (NACT)** The patient presents with a 4 cm breast lump involving the skin (T4b) and a mobile axillary lymph node (N1). According to the TNM staging system, any skin involvement (ulceration or edema/peau d'orange) classifies the tumor as **Stage IIIB (Locally Advanced Breast Cancer - LABC)**. The standard of care for LABC is **Neoadjuvant Chemotherapy (NACT)**. The primary goals are to downstage the tumor, increase the likelihood of breast-conserving surgery (BCS), and treat micrometastatic disease early. Surgery is performed only after the tumor has responded to chemotherapy. **Why other options are incorrect:** * **C & D (MRM and Simple Mastectomy):** Upfront surgery is contraindicated in LABC (Stage III). Operating on a tumor with skin involvement without prior downstaging often leads to positive margins and high recurrence rates. * **A (Radiotherapy):** Radiotherapy is a component of multimodality treatment but is typically administered *after* surgery (Adjuvant) to reduce local recurrence, not as the initial primary treatment. **Clinical Pearls for NEET-PG:** * **LABC Definition:** Includes T3 (>5cm), T4 (skin/chest wall involvement), or N2/N3 nodal status. * **T4 categories:** T4a (Chest wall), T4b (Skin: ulceration/peau d'orange), T4c (Both), T4d (Inflammatory carcinoma). * **Sequence of Management in LABC:** NACT → Surgery (MRM or BCS) → Adjuvant Radiotherapy → Hormonal/Targeted therapy (if indicated). * **Dimpling vs. Peau d'orange:** Dimpling is due to involvement of **Cooper’s ligaments** (T2/T3), whereas peau d'orange is due to **subdermal lymphatic obstruction** (T4).
Explanation: The **AJCC Cancer Staging Manual (8th Edition)** introduced a paradigm shift in breast cancer staging by moving from a purely **Anatomic Stage** (TNM) to a **Prognostic Stage**. ### Why "Age" is the Correct Answer While age is a significant risk factor for developing breast cancer and can influence treatment decisions (e.g., choosing breast-conserving surgery vs. mastectomy), it is **not** a component of the AJCC 8th Edition Prognostic Staging system. Staging is designed to reflect the biological behavior and outcome of the tumor itself, rather than patient demographics. ### Explanation of Other Options (Included in Prognostic Staging) The AJCC 8th Edition integrates biological markers with traditional TNM to provide a more accurate prognosis: * **Tumor Size (T):** Remains a fundamental part of the anatomic staging component. * **Grade (G):** Histological grade (Nottingham Grade) is now mandatory for prognostic grouping as it reflects tumor aggressiveness. * **HER-2 Status:** Along with **ER (Estrogen Receptor)** and **PR (Progesterone Receptor)** status, this molecular marker is essential for determining the Clinical and Pathological Prognostic Groups. ### High-Yield Clinical Pearls for NEET-PG * **The "Big 5" of Prognostic Staging:** To determine the Prognostic Stage Group, you need: **T** (Tumor size), **N** (Node status), **M** (Metastasis), **Grade**, and **Biomarker status** (ER, PR, and HER2). * **Oncotype DX:** In the US/specific settings, multigene assays (like the 21-gene recurrence score) are also integrated into staging for T1-T2, N0, ER+ tumors. * **Triple Negative Breast Cancer (TNBC):** Usually carries a worse prognostic stage compared to Luminal A types, even if the anatomic TNM is the same. * **Most Important Prognostic Factor:** Overall, the number of **axillary lymph nodes** involved remains the most significant prognostic factor for recurrence and survival.
Explanation: **Explanation:** The clinical presentation is classic for a **Breast Cyst**, which is the most common cause of a discrete breast lump in women aged 35–50 years (perimenopausal age group). **Why Option A is correct:** 1. **Age & Hormonal Status:** Breast cysts are most prevalent in perimenopausal women due to hormonal fluctuations. 2. **Rapid Onset:** Cysts often appear "suddenly" or enlarge rapidly, sometimes causing mild discomfort. 3. **Physical Findings:** A **fluctuant** (fluid-filled), well-circumscribed, and oval mass is the hallmark of a cyst. Solid tumors like cancer or fibroadenomas are typically firm or hard, not fluctuant. **Why other options are incorrect:** * **B. Galactocele:** These are milk-containing cysts that occur exclusively during or shortly after **lactation**. A 50-year-old perimenopausal woman is outside this clinical window. * **C. Fibroadenoma:** Known as the "breast mouse," these are typically found in younger women (15–35 years). While well-circumscribed, they are firm and rubbery, not fluctuant. * **D. Breast Cancer:** While a priority to rule out, malignancy usually presents as a hard, painless, irregular, and non-mobile mass that develops over months rather than weeks. It would not be fluctuant. **NEET-PG High-Yield Pearls:** * **Investigation of Choice:** Ultrasound (USG) is the best initial modality to differentiate a solid mass from a cystic one. * **Management:** Simple asymptomatic cysts require no treatment. If symptomatic or tense, **Fine Needle Aspiration (FNA)** is performed. * **Red Flags:** If the aspirated fluid is blood-stained or the lump recurs immediately, a biopsy is mandatory to rule out intracystic carcinoma.
Breast Anatomy and Physiology
Practice Questions
Benign Breast Diseases
Practice Questions
Breast Cancer Screening
Practice Questions
Breast Cancer: Diagnosis and Staging
Practice Questions
Surgical Management of Breast Cancer
Practice Questions
Oncoplastic Breast Surgery
Practice Questions
Sentinel Lymph Node Biopsy
Practice Questions
Axillary Surgery
Practice Questions
Breast Reconstruction Techniques
Practice Questions
Male Breast Disorders
Practice Questions
Phyllodes Tumors
Practice Questions
Management of Ductal Carcinoma In Situ
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free